Evidence map›Paper›PMID 33134863›Full record

ArticleHemaSphere2020

Fair Pricing of Innovative Medicines: An EHA Position Paper.

Anton Hagenbeek, John Gribben, Ulrich Jäger, Peter Kapitein, Giampaolo Merlini, Maria Piggin, Carin A Uyl-de Groot, Robin Doeswijk

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  2. Valuation of Medical Innovation Handling with Uncertainty and Risk.Journal of market access & health policy · 2024
    Article
  3. Review
  4. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.The European journal of health economics : HEPAC : health economics in prevention and care · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anton HagenbeekDepartment of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
John GribbenBarts Cancer Institute, Queen Mary University of London, London, UK.
Ulrich JägerMedical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Vienna, Austria.
Peter KapiteinInspire2Live, Amsterdam, The Netherlands.
Giampaolo MerliniAmyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy.
Maria PigginPNH Support, a Charitable Incorporated Organization registered with the Charities Commission of England and Wales (no. 1161518), London, UK.
Carin A Uyl-de GrootErasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
Robin DoeswijkEuropean Hematology Association, The Hague, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33134863
PMCPMC7544294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.